Sign for Notice Everyday    Sign Up| Sign In| Link|

Our Sponsors

    Receive Latest News

    Share Us

    24th Pharmacovigilance 2021 (Virtual Conference)

    View: 51

    Website | Edit Freely

    Category pharma, pharmacovigilance, drug safety

    Deadline: February 22, 2021 | Date: February 24, 2021-February 25, 2021

    Venue/Country: Online Conference, U.K.

    Updated: 2021-01-18 15:27:32 (GMT+9)

    Call For Papers - CFP

    24th Pharmacovigilance 2021

    “Latest developments in pharmacovigilance, drug safety and RMP”

    24th - 25th February 2021, Virtual Conference (Time Zone - GMT)

    This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.


    Email: or Call: +44-20 3509 3779

    Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.

    Early Bird Pricing

    1 Delegate @ £400 + VAT (Valid Till 28th January 2021)

    3 Delegates @ £1000 +VAT (Valid Till 28th January 2021)

    Standard Pricing

    1 Delegate @ £600 +VAT (Valid From 29th January 2021)

    3 Delegates @ £1400 + VAT (Valid From 29th January 2021)

    Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to .


    • WILLIAM WANG, Executive Director, Clinical Safety Statistics, Merck (USA)

    • MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Johnson & Johnson

    • WIVINA DE WAELE, Director, Regional Safety Excellence EMEA. Global Drug Safety, Alexion Pharmaceuticals

    • KHAUDEJA BANO, Executive Medical Director, Combination Product Safety Head, Amgen (USA)

    • SUMIT MUNJAL, Vice President, Global Patient Safety Evaluation, Takeda

    • JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi

    • OYINKANSOLA ODEBO, Assistant Director, Drug Safety Clinical Research, Supernus Pharmaceuticals (USA)

    • ALESSANDRO VAGHEGGINI, Associate Principal Biostatistician, Clinical Safety Statistics, Merck (USA)

    • TEA BABIC, Assoc. Dir – Audits and Inspections, Teva

    • DAVID J LEWIS, EU QPPV Head QPPV Office, Novartis

    • SHAUN COMFORT, Principal Scientific Enablement Director, Roche – Genentech

    • YUUNG YUUNG YAP, Senior International Regulatory Counsel, EU and International Regulatory Law, Pfizer

    • DAVID JEFFERYS, Sr. VP Regulatory, Eisai

    • VALENTINA MANCINI, Director PV, EU QPPV, Shionogi Europe

    • ROSALINA DOMIN, Senior Director, QA and Deviation Management Head, PV Quality, Sanofi

    • RAJ BHOGAL, Sr. Director, R&D Audits & Inspections, Jazz Pharmaceuticals

    • ANDREA OLIVA, Head of Pharmacovigilance, Mylan

    • JAYLAXMI NALAWADE, Associate Director - Pharmacovigilance & REMS, Lupin

    • FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead - Compliance & Regulatory Affairs Quality, Novartis

    • YVONNE NANCIU, Senior Manager Pharmacovigilance & Medical Information, Local QPPV, Abbvie

    • RUDI SCHEERLINCK, Global Head Pharmacovigilance Risk Management, Nestle

    • CHETAN SHATAPATHY, Principal Pharamcovigilance Physician - Oncology R&D Unit, AstraZeneca

    • JOHN POUSTIE, Senior Director, Global Pharmacovigilance, Norgine

    • SUE REES, Pharmacovigilance Expert, (Former EU QPPV Executive Director, Global Safety), Amgen

    • GAURI UTTURKAR, Senior Manager - Pharmacovigilance, Glenmark Pharmaceuticals

    • LISBETH TOFTE HEMMINGSEN, Director, Drug Safety Consult

    • NICOLE BAKER, Co-Founder, BioLogit

    • MARY LYNNE VAN POELGEEST, President, World Federation for Incontinent Patients -(WFIP)

    Plus more joining soon


    • Overcoming this Pandemic Issues - Drug Safety Strategy for Pharmaceutical organisations

    • Outsourcing in Pharmacovigilance- Best Practices, Challenges and key consideration

    • Key factors driving the current global Pharmacovigilance (PV) market?

    • Pharmacovigilance and assessment of drug safety reports during COVID 19

    • What are the market opportunities, market risk and market overview of the (PV) market?

    • PV Audit & Inspections – Keeping on the right side of Inspectors

    • Documentation (RMPs, PSURs, PADERs, PBRERs)

    • Practical approaches - Quality, Safety & Signal Detection

    • Medical devices – Increasing safety perspective

    • Improving patient safety

    • New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)

    • Brexit Implications for the Pharmaceutical (pharmacovigilance) Industry

    • RoW - Recent developments and future perspectives

    • The developing regulatory framework in advanced and developing markets – EU, USA & ROW

    • Be part of a major networking opportunity

    Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.

    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.